Hepatitis B virus Developing country Transplant-related mortality (TRM) a b s t r a c t Background: Hematopoietic stem cell transplantation (HSCT) is challenging in Hbs-Ag positive or HCV-Ab positive patients due to fear of delaying engraftment and transplant-related mortality (TRM). Very few data are published internationally till date. We had done HSCT (allogenic/autologus) of 19 hepatitis B and hepatitis C positive malignant and nonmalignant patients at our institute during the years 1999-2013. Design and methods: We performed a retrospective analysis of the patients who were either hepatitis B or hepatitis C virus seropositive at the time of HSCT (n = 19). All the positive patients (Hbs-Ag positive or HCV-Ab positive) who underwent HSCT for malignant or nonmalignant causes during 1999-2013 were selected. A total of 13 patients underwent autologus HSCT and 6 patients underwent allogenic HSCT. All the included patients had performance score 1, normal liver function test, and noninfectious state of Hbe antigen before HSCT.
1.

Introduction
The hematopoietic stem cell transplantation (HSCT) in Hbs-Ag positive/HCV-Ab positive infected patients in the world is occurring more frequently nowadays. But the hesitation is still prevalent to avoid transplant by the treating primary physician in view of increasing rates of delay of engraftment, transplant-related mortality (TRM). There are very few published data available to focus this issue.
HSCT is challenging in Hbs-Ag positive/HCV-Ab positive patients due to more complications in the form of more neutropenia, graft versus host disease (GVHD), drug toxicity of chemotherapy, acute fulminant liver failure, and fear of delay of engraftment. 1, 2 We had done HSCT (allogenic/autologus) of 19 Hbs-Ag positive/HCV-Ab positive malignant and nonmalignant patients at our institute during the years 1999-2013.
Patients and methods
All the patients underwent HSCT at our Transplant center situated in western India. Retrospectively, we collected the patient data from the hospital records, during the years 1999-2013, with Hbs-Ag positive/HCV-Ab positive patients. A total of 204 patients underwent HSCT during that period, and from that, 19 patients (9.5%) were seropositive for either Hbs-Ag or HCV-Ab. Baseline HBV-DNA and HCV-RNA titer had been done. For Hbs-Ag positive patients, Hbe Ag, anti-HBs antibody (Ab), and anti-Hbe Ab levels from the accredited laboratories have been done. Alfa fetoprotein and ultrasonography of the liver were also performed on all the recipients at every 6 months intervals. Remaining 185 patients were excluded from the study cohort because they are seronegative.
Exclusion criteria
1) Performance score 2 and 3 (using Eastern Cooperative Oncology Group score) 2) Infectious Hbs-Ag positive cases (Hbe-Ag +ve)
3) Abnormal liver function test (more than three times of upper limit of liver enzymes, >1.5 times serum bilirubin considered as abnormal).
Pre-HSCT work-up was normal for the entire patients. Written consent was taken. Hickman insertion was done by qualified anesthetist with universal precautions. We have two positive pressure HEPA filtered isolation rooms for HSCT procedures. All the blood products were irradiated before given to patients. Hbs-Ag positive cases were on antiviral therapy (entecavir/lamivudine/tenofovir) and continued during and after HSCT as per gastroenterologist advice. All the patients who underwent allogenic HSCT had related donors. Surveillance of cytomegalo virus (CMV) infection by reverse transcriptase-polymerase chain reaction (RT-PCR) had been done pre-HSCT and also frequently post-transplant and treated accordingly.
We had used conditioning regimen BCNU, etoposide, cytarabine, and melphalan (BEAM) for autologus HSCT and busulfan, cyclophosphamide (BUCY), busulfan, cyclophosphamide-thymoglobulin (BUCY-THYMO), and reduced intensity HSCT (RIST) for allogenic HSCT. Detailed description regarding regimens used in HSCT is given in Table 2. GVHD prophylaxis in allogenic HSCT was by using cyclosporine and short-term methotrexate. 3 The target cyclosporine level is set between 200 and 300 ng/ml. Grading of GVHD has been done with the Glucksberg scale. 4 Surveillance of CMV infection was done pre-HSCT by RT-PCR and also frequently post-transplant and treated accordingly. Checking of donor engrafting in case of mismatch sex was done by fluorescent in situ hybridization method and for same sex by variable number of tandem repeat short-DNA sequences studies as per the standard guidelines.
Statistical analysis
Statistical analysis was done with the Statistical Package for the Social Sciences. The Kaplan-Meier survival curves were used for the overall survival analysis of the patients. Glucksberg Scale was used for GVHD classification.
Out of 6 allogenic HSCT patients, 4 developed graft versus host disease (GVHD) (2liver, 1colon, 1both skin and liver). Three patients died due to liver GVHD (2acute, 1chronic).
Grades of GVHD in allogeneic HSCT patients are as follows, for liver (grade 3 in 2, grade 4 in 1), i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 9 5 -1 0 0 3.
Results
A total of 204 patients underwent HSCT during the years 1999-2013, and from that 19 patients (9.5%) were seropositive for either Hbs-Ag or HCV-Ab. The median age of the seropositive patients was 25 years (range 7-54). Out of a total of 19 patients, 15 patients were Hbs-Ag positive and 4 were HCV-Ab positive. We had used BEAM regimen for autologus HSCT and BUCY, BUCY-THYMO, and RIST regimen for allogenic HSCT. Most common indication of HSCT was Hodgkin's lymphoma (n = 7), followed by non-Hodgkin's lymphoma (NHL) (n = 5), leukemia (n = 4) (acute myeloid leukemia (AML) = 3, chronic myeloid leukemia = 1), thalassemia (n = 2), and multiple myeloma (MM) (n = 1). Out of 19 patients, 16 were males and 3 were females. Baseline characteristics, demographic profile, viremic status, conditioning regimen used, and transplant outcomes are depicted in Table 1 .
3.1.
Indications for the transplant and outcome
Hodgkin disease (HD)
Most common histology was mixed cellularity. A total of 5 patients of HD were in 3rd complete remission (CR) and 2 patients were in 2nd CR during HSCT. One patient expired at home after 2 years of HSCT. One patient relapsed within 2 months and is doing well on lenalidomide at present.
NHL
A total of 3 patients had B-cell and 2 patients had T-cell lymphoma. 3, 1, and 1 patients of NHL were in 3rd CR, 2nd CR, and 4th CR, respectively. Engraftment had not occurred in 4th CR patient and nontransplant-related disease mortality occurred in 1 patient (death due to myocardial infarction). Overall percentage of engraftment, 100 days survival, 1-year OS, and 5-year OS for lymphoma patients were 91.6%, 91.6%, 91.6%, and 77.7%, respectively.
Leukemia
A total of 2 patients of AML were of 1st CR, 1 patient of AML was in 2nd CR, and 1 patient was of chronic myeloid leukemiachronic phase (intermediate risk according to Sokal and Hasford score). 5, 6 Overall percentage of engraftment, 100 days survival, 1-year OS, and 5-year OS for leukemia patients were 100%, 75%, 50%, and 0%, respectively. Cause of death was severe liver GVHD in 3 patients. 1 patient expired at 1 year after HSCT due to ARDS (acute respiratory distress syndrome).
Thalassemia
There were 2 patients and both were of high risk (Class 3-Lucarelli Staging). 7 Both were heavily transfused previously and were HCV-Ab positive. GVHD did not occur in any patient. Both the patients are alive and transfusion is independent at present.
MM
Our first patient was of MM. Patient was in 3rd CR during HSCT. Patient is alive and disease free at present. Patient did not require second HSCT.
Transplant outcomes
Neutropenia, febrile episodes, neutrophils engraftment, and platelet engraftment
All the patients underwent successful engraftment except one NHL patient. The median duration of neutropenia was 14 days (5-27) and 11 (5-66) days in the allo-HSCT and auto-HSCT, respectively. Eight-six percent of the patients in the allogenic HSCT group and 93% of the patients in the autologus HSCT group had at least one febrile episode during their neutropenic period. Median duration for engraftment of neutrophils was achieved on +Day 17 with 3 consecutive absolute neutrophil counts of more than 500 cumm/dL. Median duration for engraftment of platelets was achieved on +Day 19 with 3 consecutive platelet counts of more than 50,000 cumm/dL without any component support.
Supportive measures and GVHD prophylaxis in allogenic HSCT patients
Initially supportive measures were taken to correct low hemoglobin and platelet count.
Ursodeoxycholic acid 12 mg/kg/day was given orally from the day before starting the conditioning regimen until +Day 90 after transplant to prevent the veno-occlusive disease (VOD). Oral cyclosporine 5 mg/kg was started from ÀDay 1 and continued to +Day 60 to prevent GVHD. IV methotrexate was given on +Day 1, +Day 3, +Day 6, and +Day 11 as GVHD prophylaxis. All the patients were given prophylactic antibacterial, antifungal, and anti-P. jirovecii treatment during allogenic HSCT procedure. Cyclosporine and acyclovir were continued for 6 and 12 months, respectively.
Median 100 days, 1-year OS, and 5-year OS (overall survival) ( Fig. 1) were 89.4%, 94.1%, and 81.1%, respectively ( Table 2) . Average cost for allo-and autologus HSCT were 11,220 USD and 8100 USD, respectively. All the allogenic HSCT patients were positive for CMV infection and were treated with ganciclovir. Out of 6 allogenic HSCT patients, 4 developed GVHD (2liver, 1colon, 1both skin and liver). Grades of GVHD in allogeneic HSCT patients according to Glucksberg Scale are as follows, for liver (grade 3 in 2, grade 4 in 1), colon (grade 2 in 1), and skin (grade 2 in 1). Three patients died due to liver GVHD (2acute, 1chronic). i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 9 5 -1 0 0 4.
Discussion
HSCT is challenging in Hbs-Ag positive or HCV-Ab positive patients due to more complications in the form of more neutropenia, GVHD, drug toxicity of chemotherapy, acute fulminant liver failure, and fear of delaying of engraftment. 6, 7 The much higher level of antimicrobial resistance and poor quality of the environment in developing countries make it prudent to have a dedicated unit where there is a high level of control of the environment. 8 HSCT in tropical countries poses a significant problem in terms of unusual infections. All patients transplanted at our center are positive for CMV IgG, unlike in the West where over 30% of patients and donors are CMV negative. We do not administer antituberculosis or antimalarial drugs prophylactically.
Hbs-Ag positive infection and HSCT
Patients may come to HSCT already infected with hepatitis B virus (HBV). These patients are potentially at risk for VOD and/or recurrent HBV infection after transplantation. Preexisting cirrhosis or marked hepatic fibrosis does increase the risk of severe VOD and multiorgan failure and should be considered a contraindication to high-dose cytoablative therapy and HSCT. Underdeveloped countries like India are more prone for HBV infection because chronic HBV (Hbs-Ag positive) infection is endemic in Asia, Southern Europe, and Latin America, where the prevalence of chronic Hbs-Ag positive infection in the general population ranges from 2% to 20%. The increased use of immunosuppressive or cytotoxic therapy has led to increased concern of the impact of immunosuppressant on the natural history of chronic Hbs-Ag positive infection. 9 The risk of fatal HBV liver disease among patients who are persistently Hbs-Ag positive after transplantation is $12%. With the introduction of preemptive antiviral treatment, the incidence of hepatitis due to Hbs-Ag positive reactivation in the immediate post-HSCT period has been drastically reduced. 10, 11 Previously, cirrhosis has been demonstrated to be an important late complication of HSCT and is most often due to chronic hepatitis C virus. However, the long-term outcome of these Hbs-Ag recipients of allogeneic HSCT is unknown. [12] [13] [14] 
HCV-Ab positive infection and HSCT
There is no consensus regarding the usefulness of ribavarin or alpha-interferon in HCV-Ab positive patients 15, 16 and hence we have not used it in our HCV-Ab positive patients. Data have shown higher rate of liver fibrosis in HSCT patients as compared with HCV-Ab positive infected patients who did not receive a transplant. 17 Our patients did not develop this complication till date, and still longer follow-up is required. The influence of chronic hepatitis C on the outcomes after allogeneic HSCT is not clearly defined. A few studies have suggested an increase in the rate of VOD, 18, 19 a finding which has not been corroborated in other series. 20 Moreover, HSCT recipients showed a higher rate of liver fibrosis progression as compared with HCV-infected patients who did not receive a transplant. Liver biopsy should be considered before the start of conditioning therapy if there is a clinical suspicion of cirrhosis or extensive fibrosis resulting from chronic viral infection. Pathological distinctions between HCV and GVHD may be difficult, as both are associated with portal lymphoid infiltration and bile duct injury. A 9.6fold increased risk of fatal SOS was demonstrated in HCVinfected patients who received cyclophosphamide and TBI over 12 Gray, related to sinusoidal toxins of those regimens and not directly to HCV. Even though the rate of hematopoietic recovery like neutrophils and platelet recovery was lower in the HCV-Ab positive group, we are not able to compare with the HCV-Ab negative because of our study design. A multivariate analysis revealed that HCV-Ab seropositivity was associated with an independent risk for higher nonrelapse mortality (hazard ratio: 1.65, P < 0.01) and inferior overall survival (hazard ratio: 1.39, P < 0.01). The incidences of death due to hepatic problems (8% vs. 2%, P < 0.01), bacterial infection (10% vs. 4%, P < 0.01), or graft failure (5% vs. 2%, P = 0.084) tended to be higher in the HCV-Ab-positive group. 21 In a study by Gérard Socié et al. shows median overall survival is dismal in the HCV infected transplant candidates as compared to the HCV-negative control groups. Nonrelapse mortality at one year was also more in HCV-infected transplant candidates as compared to HCV-negative patients. Thus, HCV seropositivity remained a significant risk factor for nonrelapse mortality after allogeneic HSCT even with normal or minimally abnormal liver function tests. 22 i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 9 5 -1 0 0 5.
Limitation
Limitation of our study is that we are not able to compare the study cohort with the seronegative patients who have undergone HSCT because of study's small sample size and nonrandomization of the study population.
Conclusion
HSCT is a rugged job in Hbs-Ag positive or HCV-Ab positive patients due to more complications in the form of more neutropenia, GVHD, drug toxicity of chemotherapy, acute fulminant liver failure, fear of delaying of engraftment, and TRM. Larger sample size and randomized controlled trials are required to focus an adverse impact of Hbs-Ag positive and HCV-Ab positive seropositivity on the clinical outcome following HSCT. Careful evaluation before embarking on HSCT and intensive assessment against complications are warranted in Hbs-Ag positive and HCV-Ab positive recipients. We strongly believe that if the study was done in a randomized controlled fashion with good number of subjects, results would have been more meaningful in transplant-related outcomes in seropositive and nonseropositive population undergoing HSCT.
